文献速递心胸血管麻醉

抑肽酶的血小板保护特性:机制与临床效果的范围综述

Platelet-sparing properties of aprotinin: A scoping review on mechanisms and clinical effects.
PubMed 文献 · Eur J Anaesthesiol · 2024-10-11

BACKGROUND: Cardiac surgery involving cardiopulmonary bypass (CPB) is associated with the risk of acquired coagulopathy, including dysregulated fibrinolysis, which can result in life-threatening bleeding complications.…

要点

  • 抑肽酶的血小板保护效应多被归因于抑制血小板聚集、黏附、活化及受体蛋白水解。
  • 体外研究和随机对照试验对血小板保护效应的剂量依赖性结果不一致。
  • 尚无研究探讨血小板保护效应与抗纤溶效应在减少失血和输血中的相对贡献。

核心结论

  • 综述阐明了抑肽酶影响血小板并发挥血小板保护效应的现有知识,同时指出了文献空白。

主要发现

  • 多数研究观察到血小板保护效应,机制包括保护GP IIb/IIIa受体抑制聚集、保护GP Ib受体抑制黏附、蛋白酶激活受体1蛋白水解、抑制纤溶酶和凝血酶以抑制血小板活化。
  • 体外研究和随机对照试验对血小板保护效应的剂量依赖性得出混合结果。
  • 尚无研究探索抑肽酶血小板保护效应与抗纤溶效应在减少失血和输血需求中的相对贡献。

局限性

  • 现有文献存在空白,血小板保护效应的生化通路尚不明确,其临床贡献程度不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiac surgery involving cardiopulmonary bypass (CPB) is associated with the risk of acquired coagulopathy, including dysregulated fibrinolysis, which can result in life-threatening bleeding complications. Aprotinin, an antifibrinolytic agent, has been recommended for the prevention of these complications. Its effectiveness has been attributed to its ability to nonspecifically inhibit various serine proteases involved in the coagulation and fibrinolysis cascade. Additionally, aprotinin may protect platelets from CPB-induced dysfunction through a platelet-sparing effect, further enhancing its efficacy. OBJECTIVES: The biochemical pathways underlying aprotinin's platelet-sparing effect remain unclear. Furthermore, it is uncertain to what extent this effect contributes to reducing blood loss and need for transfusion. DESIGN: A scoping review. DATA SOURCES: MEDLINE, Embase and Cochrane were searched from inception until 21 December 2023. ELIGIBILITY CRITERIA: Studies in which a platelet-sparing effect of aprotinin was investigated. These included systematic reviews; experimental, and observational studies describing healthy humans, patients, or animals undergoing any type of surgery; studies in which donated blood was used for in-vitro studies. RESULTS: Sixty-four studies were deemed eligible, the majority of which observed a platelet-sparing effect, attributing it to the inhibition of platelet aggregation (via protection of glycoprotein (GP) IIb/IIIa receptors), platelet adhesion (by protection of GP Ib receptors), both aggregation and adhesion receptors, proteolysis of protease-activated receptor 1 receptors, platelet activation (by inhibition of plasmin) and platelet activation (by inhibition of thrombin). A dose-dependency of the platelet-sparing effect was investigated in both in-vitro studies and randomised controlled trials, yielding mixed results. No studies have explored the relative contribution of aprotinin's platelet-sparing effect and its antifibrinolytic effect in reducing blood loss and need for transfusion. CONCLUSIONS: This review elucidated current knowledge on how aprotinin influences platelets and exerts its platelet-sparing effect, while highlighting gaps in the existing literature.

来源:Eur J Anaesthesiol,查看原文。版权归原作者所有。

引用

  1. Vanglabeke LLW, Rex S, Van den Eynde R, et al. Platelet-sparing properties of aprotinin: A scoping review on mechanisms and clinical effects. Eur J Anaesthesiol. 2024. PMID: 39628415. doi:10.1097/EJA.0000000000002081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。